Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review

Key Points

• Immune responses varied significantly among patients receiving CAR T-cell therapy for lupus.
• Approximately 32% of patients showed positive biomarkers indicating therapy efficacy.
• Assessment was conducted through an open-label pilot study with multiple outcomes tracked.
• Findings suggest the need for tailored approaches in treating systemic lupus erythematosus patients.